Following a succession of exciting results from trials of ProMetic’s antifibrotic candidate PBI-4050, investors can be forgiven for having forgotten about the Company’s most advanced clinical candidate Plasminogen. This week the program came right back into the spotlight with the announcement that the trial had successfully met its primary and secondary end points with a 100% success rate and even more encouragingly for patients a 100% clinical response rate with lesions healing w
28 Oct 2016
Fantastic results from pivotal Phase 2/3 Plasminogen trial
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Fantastic results from pivotal Phase 2/3 Plasminogen trial
ProMetic Life Sciences (PLI:TSE) | 0 0 1.3% | Mkt Cap: 1,075m
- Published:
28 Oct 2016 -
Author:
Derren Nathan -
Pages:
6
Following a succession of exciting results from trials of ProMetic’s antifibrotic candidate PBI-4050, investors can be forgiven for having forgotten about the Company’s most advanced clinical candidate Plasminogen. This week the program came right back into the spotlight with the announcement that the trial had successfully met its primary and secondary end points with a 100% success rate and even more encouragingly for patients a 100% clinical response rate with lesions healing w